Supplementary Figure 5: Xenograft models of KRASG13D and KRASQ61K are insensitive to RMC-4550. | Nature Cell Biology

Supplementary Figure 5: Xenograft models of KRASG13D and KRASQ61K are insensitive to RMC-4550.

From: RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Supplementary Figure 5

Daily oral administration of RMC-4550 (30 mg/kg) to athymic nude mice bearing (a) HCT-116 (KRASG13D) or (b) CALU-6 (KRASQ61K) xenograft tumors did not produce significant tumor growth inhibition. Treatment with RMC-4550 was well tolerated in both models, as assessed by body weight (c,d). Source data is provided in Supplementary Table 9.

Back to article page